Thymosin Alpha-1 is a 28-amino-acid thymic peptide that tunes the immune system — not muscle.

Start here

Thymosin Alpha-1 is a small protein the body makes in the thymus — a gland behind the breastbone that trains the immune system. Scientists copied it into a lab-made drug called thymalfasin, which is the exact same molecule. It is an immune peptide: it nudges immune cells to do their job. It does not build muscle, and there is no evidence it does. Doctors abroad have used it for decades for long-term liver infections (chronic hepatitis) and to help worn-down immune systems; it is not approved for sale in the United States. The studies are real but uneven, and many come from a single region. The most careful, biggest test — a 2025 sepsis trial in over a thousand patients — found no benefit ^[3]. This site reads that record straight, study by study. What people actually report — the upsides and the downsides — is on the Thymosin Alpha-1 effects page.

01 — A consistent immune signature across four decades

Thymosin Alpha-1 (Tα1) was isolated from calf thymus and sequenced in 1977 by Goldstein and colleagues, who established its 28-residue, N-terminally acetylated structure ^[1]. The molecule is cleaved in the body from a larger precursor, prothymosin alpha (the parent protein it is cut out of). Across the literature since, one signature recurs: Tα1 acts at the innate-adaptive interface — the handoff point where the immune system's fast, general defenses brief its slow, targeted ones. It signals through Toll-like receptors (TLR2 and TLR9, pattern sensors on immune cells) on dendritic cells (the immune system's scouts), driving them to mature and present antigen, which in turn matures T cells ^[5][11]. A thymosin alpha 1 mechanism of action breakdown sits on its own page.

What makes the molecule unusual is a dual effect. The same peptide that primes T-helper-1 (Th1) immunity also activates an enzyme called IDO that generates regulatory T cells ^[5]. In plain terms: it can wake up a sluggish immune system while keeping an overactive one in check. That two-handed action is the through-line of the Thymosin Alpha-1 research.

02 — Where the evidence is strongest, and where it is null

The record is not uniform, and an honest reading says so. The strongest, most consistent signals are in chronic viral hepatitis and as an immune-restorative adjunct. In chronic hepatitis B, 1.2 mg of Tα1 for 24 weeks raised intrahepatic natural killer T cells and cytotoxic T cells, and 28.6% of patients reached normalized ALT with undetectable HBV-DNA at 48 weeks ^[8].

Sepsis is where the appraisal turns. The earlier ETASS trial (361 patients) reported 28-day mortality of 26.0% with Tα1 versus 35.0% in controls — a roughly nine-point gap that did not reach conventional significance (nonstratified P=0.062) ^[2]. Then the phase-3 TESTS trial — 1,106 adults across 22 centres, double-blind and placebo-controlled, the largest and most rigorous to date — found no difference: 23.4% versus 24.1%, hazard ratio 0.99 (95% CI 0.77-1.27), P=0.93 ^[3]. The biggest, best-designed sepsis study came back null. That result is the spine of how this site reads everything else.

03 — A different molecule from the ones it is confused with

Thymosin Alpha-1 is constantly mixed up with other thymic peptides. It is not thymosin beta-4 (the 43-amino-acid actin-binding peptide marketed in research circles as TB-500) — in fact, in the human mixed lymphocyte reaction the two had opposing roles: Tα1 enhanced proliferative responses via helper T cells while thymosin beta-4 suppressed them ^[15]. It is also distinct from thymulin (a zinc-dependent nonapeptide), thymopentin (a pentapeptide), thymalin (a separate bovine thymic-extract preparation), and from prothymosin alpha, its own larger precursor. The side-by-side distinction is drawn carefully on the thymosin alpha 1 vs thymosin beta 4 section. If you are arriving from a bodybuilding query, the short answer is plain: this is an immune peptide, and the literature gives no reason to think it builds muscle.

How to read this digest

The pages here are organized to be read in any order. The thymosin alpha 1 mechanism of action page explains how the peptide works at the cellular level; what is Thymosin Alpha-1 covers its structure, names and origin; the Thymosin Alpha-1 research page walks the human trials by indication and grades the evidence; the dosage page reports the figures that appeared in those trials, by population and route; and the Thymosin Alpha-1 effects page sets the community's reported experiences — clearly labeled anecdotal — beside the cited safety record. Throughout, the rule is the same: lead with what was measured, attribute it to its source, and mark the difference between what the strongest evidence shows (chronic hepatitis, immune restoration) and where the largest trial found nothing (sepsis). Numbers are reported as research data, never as advice.

What this site is

Review TA1 is an independent editorial project. It reads the peer-reviewed Thymosin Alpha-1 literature and reports what each study measured, with every quantitative claim tied to a numbered source on the Thymosin Alpha-1 references page. It is not a clinic, not a pharmacy, and nothing here is for sale. The dosing page reports figures only as they appeared in trials — by population and route — never as instructions to anyone.